Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 31,307 shares, a growth of 76.0% from the September 30th total of 17,790 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 54,073 shares, the days-to-cover ratio is currently 0.6 days.
Shuttle Pharmaceuticals Stock Down 3.9%
Shares of SHPH stock traded down $0.20 during mid-day trading on Monday, reaching $4.95. The company’s stock had a trading volume of 92,129 shares, compared to its average volume of 759,528. The company’s 50 day simple moving average is $4.18 and its 200-day simple moving average is $7.13. Shuttle Pharmaceuticals has a 12-month low of $2.58 and a 12-month high of $44.40. The firm has a market capitalization of $23.56 million, a PE ratio of -0.27 and a beta of -0.04.
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on SHPH
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue.
Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.
Further Reading
- Five stocks we like better than Shuttle Pharmaceuticals
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
